...A status report of each postmarketing study of the drug product concerning clinical safety.....FDA will maintain a requirement for reporting data from all ongoing product stability studies.....Most of the information contained in these reports is different from the information..
http://www.fda.gov/OHRMS/DOCKETS/98fr/103000c.htm (score=100)

MDI and DPI Drug Products
...The guidance sets forth information that should be provided to ensure continuing drug.....manufacturing, processing, packaging, controls, stability testing, or labeling operations.....with characteristics unique to the design, will present challenges in developing..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=67)

stability guidance -draft
...useful support data for establishing the expiration date, provide product stability information or.....Significant change for a drug product at the accelerated stability condition and the.....Communications Management, Drug Information Branch, HFD-210, 5600 Fishers Lane, Rockville..
http://www.fda.gov/cder/guidance/1707dft.pdf (score=53)

Guidance- Content & Format CMC for Vaccine & Related Product
...A description should be provided of the potency assay for the drug product.Information should be.....the evidence derived from validation studies which assures that product identity, purity, potency, and stability is preserved for.....material at each holding step, as outlined in "Stability Testing of New Drug Substances..
http://www.fda.gov/cber/gdlns/cmcvacc.pdf (score=44)

þÿ
...18 The applicant and/or drug product manufacturer must establish the reliability of the.....recommends that the drug substance information be included in a master file or incorporated in the.....should explain the scientific reasons why a stability indicating procedure is not viable..
http://www.fda.gov/cder/guidance/3969DFT.pdf (score=38)

þÿ
...18 The applicant and/or drug product manufacturer must establish the reliability of the.....recommends that the drug substance information be included in a master file or incorporated in the.....should explain the scientific reasons why a stability indicating procedure is not viable..
http://www.fda.gov/OHRMS/DOCKETS/98fr/2003d-0571-gdl0001.pdf (score=37)

Pediatric Rule
...In the development of a new drug or biological product, decisions about appropriate populations to study and.....provision to the Office of Information and Regulatory Affairs, OMB, New Executive Office.....demonstrating adequate product stability, bioavailability, and.. production process..
http://www.fda.gov/cder/guidance/pedrule.pdf (score=34)

Safety and Effectiveness of New Drugs & Biological Products in Pediatric...
...23 would authorize FDA to require a manufacturer of a marketed drug or biological drug product to submit an.....FDA has taken a number of steps in recent years to address inadequate pediatric drug testing and inadequate pediatric use.....product stability, bioavailability, and production process validation. While such costs would vary..
http://www.fda.gov/cder/guidance/pedrule.htm (score=34)

Packaging
...It should provide an adequate seal, be compatible with the drug product, and not be a source of.....This information should include the proposed market package for the product and the relevant stability and.....If a medicine dropper is incorporated as an integral part of the drug container or closure, pertinent information on materials..
http://www.fda.gov/cder/guidance/package.htm (score=30)

FR Doc 04-4249
...For example, if an OTC drug manufacturer made and sold a particular drug product, that drug product would have a.....The comment explained that placing a bar code on such products would present a drug stability.....It added that the additional information would provide better information about the..
http://www.fda.gov/OHRMS/DOCKETS/98fr/04-4249.htm (score=26)

Microsoft Word - 5320.1.doc
...Description of the Composition of the Drug Product..Description of the drug product composition.....process and validation information for a sterile drug substance is the same as..for a.....2 Post-Approval Stability Protocol and Stability Commitment.. Analytical procedures and testing schedule for..
http://www.fda.gov/cder/mapp/5320.1.pdf (score=26)

IND content and format for Phase 1 studies
...As clinical development of a drug product proceeds,sponsors should discuss the manufacturing.....Flow diagrams are suggested as the usual,most effective, presentations of this information.....methods used to monitor the stability of the drug..product packaged in the proposed..
http://www.fda.gov/cder/guidance/phase1.pdf (score=25)

Content and Format of INDs for Phase 1 Studies of Drugs, Inclu
...used to monitor the stability of the drug product packaged in..the proposed container/closure system and storage.....drug, the amount of information needed to make that assurance will vary..with the phase of the investigation.....Information on the drug product should be submitted in a summary..report containing the..
http://www.fda.gov/cder/guidance/clin2.pdf (score=25)

Microsoft Word - 5020.1.doc
...Description of the Composition of the Drug Product..Description of the drug product composition.....process and validation information for a sterile drug substance is the same as..for a.....2 Post-Approval Stability Protocol and Stability Commitment.. Analytical procedures and testing schedule for..
http://www.fda.gov/cder/mapp/5020.1.pdf (score=25)

Substance
...individual batches of the drug substance used in animal and clinical testing, Drug.....In addition to details of the manufacturing process and the in-process controls.....relation to the amount of crude product, whether it is filtered while hot, whether a..
http://www.fda.gov/cder/guidance/drugsub.pdf (score=24)

WAIS Document Retrieval
...Final specifications for the drug substance and drug product are not expected until the end of the investigational.....During Phase 1, sufficient information about the drug's pharmacokinetics and.....For example, although stability data are required in all phases of the IND to demonstrate..
http://www.fda.gov/cber/ind/21cfr312.htm (score=24)

Format and Content for the CMC Section of an Annual Report
...regulations have exhibited wide variability from firm to firm, and at times the.....Regulatory specifications and analytical methods for the drug substance and drug..product should be listed.....Documentation for the Stability of Human Drugs and Biologics provides information on..the design of stability protocols..
http://www.fda.gov/cder/guidance/cmc1.pdf (score=24)

Guidance for Industry Botanical Drug Products
...22, an IND must contain sufficient information to demonstrate that the drug product is safe for testing in humans and that the.....The sponsor should develop stability-indicating analytical methods and conduct stability.....These regulations require documentation of the drug substance, drug product, placebo, labeling, and an..
http://www.fda.gov/cder/guidance/4592fnl.htm (score=22)

Document
...foreign marketing developments with treatment use under a treatment pro-the drug during.....report shall be submitted as soon as participation in the study was com-the relevant.....drug product and those which with additional information pertinent ..may not appear but which..
http://www.fda.gov/cber/ind/21cfr312.pdf (score=22)

...22, an IND must contain sufficient information to demonstrate that the drug product is safe for testing in humans and that the.....The sponsor should develop stability-indicating analytical methods and conduct stability.....The stability of a botanical drug substance or product generally should not be based entirely on the assay of the active constituents..
http://www.fda.gov/cder/guidance/4592fnl.doc (score=21)

Las Vegas Injury Lawyer